Literature DB >> 30836432

No evidence of increased cerebrovascular involvement in adult neurologically-asymptomatic β-Thalassaemia. A multicentre multimodal magnetic resonance study.

Immacolata Tartaglione1, Camilla Russo2, Andrea Elefante2, Martina Caiazza1, Maddalena Casale1, Rosanna Di Concilio3, Angela Ciancio4, Elisa De Michele5, Giovanni Amendola3, Paolo Gritti6, Pasquale A Carafa7, Teresa Ferrantino6, Antonella Centanni8, Noemi Ippolito8, Violetta Caserta6, Tiziana Oliveto8, Ilaria Granato8, Gianluca Femina9, Fabrizio Esposito9, Sara Ponticorvo9, Andrea G Russo9, Antonietta Canna9, Mario Ermani10, Mario Cirillo11, Silverio Perrotta1, Renzo Manara9.   

Abstract

Multi-factorial causes jeopardize brain integrity in β-thalassaemia. Intracranial parenchymal and vascular changes have been reported among young β-thalassaemia patients but conventional magnetic resonance imaging (MRI) findings are contradictory making early MRI and magnetic resonance angiography (MRA)/venography monitoring a matter of debate. This study prospectively investigated 75 neurologically asymptomatic β-thalassaemia patients (mean-age 35·2 ± 10·7 years; 52/75 transfusion-dependent; 41/75 splenectomised) using a 3T magnetic resonance scanner; clinical, laboratory and treatment data were also collected. White matter ischaemic-like abnormalities, intracranial artery stenoses, aneurysms and sinus venous thrombosis were compared between patients and 56 healthy controls (mean-age 33·9 ± 10·8 years). No patient or control showed silent territorial or lacunar strokes, intracranial artery stenoses or signs of sinus thrombosis. White matter lesions were found both in patients (35/75, 46·7%) and controls (28/56, 50·0%), without differences in terms of number (4·0 ± 10·6 vs. 4·6 ± 9·1, P = 0·63), size and Fazekas' Score. Intracranial aneurysms did not differ between patients and controls for incidence rate (7/75, 9·3% vs. 5/56, 8·9%), size and site. Vascular and parenchymal abnormality rate did not differ according to treatments or clinical phenotype. According to this study, asymptomatic β-thalassaemia patients treated according to current guidelines do not seem to carry an increased risk of brain and intracranial vascular changes, thus weakening recommendations for regular brain MRI monitoring.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  brain MRI; thalassaemia; thrombosis; transfusion medicine; vascular malformations

Mesh:

Year:  2019        PMID: 30836432     DOI: 10.1111/bjh.15834

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Lower white matter volume in beta-thalassemia associated with anemia and cognitive performance.

Authors:  Soyoung Choi; Richard M Leahy; John C Wood
Journal:  Am J Hematol       Date:  2020-04-07       Impact factor: 10.047

2.  Cerebral venous sinus thrombosis and aneurysm in a patient with double heterozygous beta-thalassemia major: A case report.

Authors:  Rui Gu; Yao Xiong; Li Li; Xiaoling Zhao; Yan Liu
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

3.  Asymptomatic intracranial aneurysms in beta-thalassemia: a three-year follow-up report.

Authors:  Renzo Manara; Martina Caiazza; Rosanna Di Concilio; Angela Ciancio; Elisa De Michele; Caterina Maietta; Daniela Capalbo; Camilla Russo; Domenico Roberti; Maddalena Casale; Andrea Elefante; Fabrizio Esposito; Sara Ponticorvo; Andrea Gerardo Russo; Antonietta Canna; Mario Cirillo; Silverio Perrotta; Immacolata Tartaglione
Journal:  Orphanet J Rare Dis       Date:  2020-01-20       Impact factor: 4.123

4.  Brain iron content in systemic iron overload: A beta-thalassemia quantitative MRI study.

Authors:  Renzo Manara; Sara Ponticorvo; Immacolata Tartaglione; Gianluca Femina; Andrea Elefante; Camilla Russo; Pasquale Alessandro Carafa; Mario Cirillo; Maddalena Casale; Angela Ciancio; Rosanna Di Concilio; Elisa De Michele; Nikolaus Weiskopf; Francesco Di Salle; Silverio Perrotta; Fabrizio Esposito
Journal:  Neuroimage Clin       Date:  2019-10-25       Impact factor: 4.881

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.